Kymab Archives -

Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category

Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema

https://pharmaphorum.com/news/key-drug-in-sanofis-1-45bn-kymab-buyout-shows-promise-in-eczema/

Sanofi is to acquire UK biotech Kymab in a deal worth up to $1.45 billion as the big

Sanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bn

https://pharmaphorum.com/news/sanofi-buys-uks-kymab-and-inflammatory-disease-hopeful-for-1-45bn/

A record number of health and medtech companies have been included in the Sunday Times Sage Tech Track

Record number of health firms feature in UK top 100 private tech list

https://pharmaphorum.com/news/babylon-among/

UK and Chinese antibody companies collaborate in immuno-oncology

Kymab signs immuno-oncology deal for bi-specific antibodies

https://pharmaphorum.com/news/kymab-signs-immuno-oncology-deal-bi-specific-antibodies/

Biotech’s Kymouse could hold the key to vaccines.

UK’s Kymab could help develop HIV vaccine

https://pharmaphorum.com/news/uks-kymab-help-develop-hiv-vaccine/

Kymab, F-star and Mission Therapeutics among crop of new UK biotechs.

Will the UK ever produce a world-class biotech company?

https://pharmaphorum.com/views-and-analysis/will-uk-ever-produce-world-class-biotech-company-2/

Kymab